In fibroblasts and fibrotic diseases, such as systemic sclerosis and CCl4-induced liver fibrosis, another SMAD-independent TGF-β1 activation pathway has been described that activates JAK2 and STAT3 [45–48]. Here, JAK2 is linked to systemic sclerosis.